Related content

Dendritic cell-based vaccines: barriers and opportunities

By Cintolo Jessica A   Datta Jashodeep   Mathew Sarah J   Czerniecki Brian J  

Future Oncology, Vol. 8, Iss. 10, 2012-10 ,pp. : 1273-1299

Future Medicine

Access to resources Recommend Favorite

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

By Galea-Lauri Joanna   Wells James   Darling David   Harrison Phillip   Farzaneh Farzin  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 11, 2004-11 ,pp. : 963-977

Springer Publishing Company

Access to resources Recommend Favorite

Dendritic Cell-Based Vaccines in Cancer: Clinical Experience to Date

By Morse M.A.   Mosca P.J.   Clay T.M.   Lyerly H.K.  

American Journal of Cancer, Vol. 1, Iss. 5, 2002-01 ,pp. : 313-322

Adis International

Access to resources Recommend Favorite

Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma

By Ren Pengfei   Ye Hua   Dai Liping   Liu Mei   Liu Xinxin   Chai Yurong   Shao Qing   Li Yang   Lei Ningjing   Peng Bo   Yao Wu   Zhang Jianying  

Oncology Reports, Vol. 30, Iss. 5, 2013-11 ,pp. : 2297-2303

Spandidos Publications

Access to resources Recommend Favorite

Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture

By Dubsky Peter   Hayden Hubert   Sachet Monika   Bachleitner-Hofmann Thomas   Hassler Michaela   Pfragner Roswitha   Gnant Michael   Stift Anton   Friedl Josef  

Cancer Immunology, Immunotherapy, Vol. 57, Iss. 6, 2008-06 ,pp. : 859-870

Springer Publishing Company

Access to resources Recommend Favorite